mpact is the name of the p3 trial that showed adding abraxane to gemcitabine increased median survival over gemcitabine by itself. It’s published. Yes abraxane was approved in pancreatic cancer based on mpact.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-10
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
0.001(1.39%) |
Mkt cap ! $19.55M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.4¢ | 7.0¢ | $3.885K | 53.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4027 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 39756 | 2 |
View Market Depth
| Last trade - 12.09pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.001 ( 1.41 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.2¢ | 7.2¢ | 7699 | ||
| Last updated 11.34am 07/06/2024 ? | |||||
| ATX (ASX) Chart |